Currency In USD
| Previous Close | 0.52 |
| Open | 0.56 |
| Day High | 0.56 |
| Day Low | 0.48 |
| 52-Week High | 2.44 |
| 52-Week Low | 0.47 |
| Volume | 37,274 |
| Average Volume | 857,050 |
| Market Cap | 20.39M |
| PE | -2.87 |
| EPS | -0.17 |
| Moving Average 50 Days | 0.7 |
| Moving Average 200 Days | 1.31 |
| Change | -0.03 |
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
GlobeNewswire Inc.
Feb 09, 2026 12:15 PM GMT
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in th
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec.
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent sur